38 results about "Arginine hcl" patented technology

Stable liquid pharmaceutical compositions comprising an antagonist anti-CD40 antibody as a therapeutically or prophylactically active component and methods useful in their preparation are provided. These compositions comprise the antagonist anti-CD40 antibody, a buffering agent to maintain the pH of the composition between about pH 5.0 and about pH 7.0, and an amount of arginine-HCl sufficient to render the liquid composition near isotonic. The stable liquid antagonist anti-CD40 antibody-containing pharmaceutical compositions of the invention find use in methods for treating proliferative diseases and diseases having an autoimmune and / or inflammatory component.

The invention discloses compound amino acid injecta, which contains arginine hydrochloride, histidine monohydrochloride, leucine, isoleucine, lysine hydrochloride and the like; meanwhile, the invention further discloses a preparation method of the compound amino acid injecta (18AA); in the event of ensuring the product quality, the compound amino acid injecta has the characteristics of saving energy and enhancing efficacy; by means of repetitive verification on precision, detection limit, quantitation limit, linear range and the like, a simple, convenient, rapid and reliable method with cleaning verification is ensured; furthermore, the residual quantity of antioxygen, namely sodium hydrogensulfite, in the compound amino acid injecta and sulphate ion generated by degrading sodium hydrogensulfite are detected according to an ion chromatography principle, thus, the amount of the antioxygen charged in the raw material proportioning can be accurately measured, and the stability of the raw material proportioning process is judged according to the measurement result; and a detection method of the compound amino acid injecta provided by the invention is an online derivative amino acid content measuring method, the speed is rapid, and the method is applied to large-scale detection.

The present invention relates to a stabilized pharmaceutical preparation of R27T, the preparation comprising a human interferon beta variant (R27T), an acetate buffer, arginine, trehalose, Poloxamer 188, and methionine. The stabilized R27T pharmaceutical preparation according to the present invention is obtained by the development of a preparation having a novel composition through the substitution of mannitol with trehalose in the composition of a preparation containing mannitol, which was previously studied by the present inventors. It was confirmed that the preparation can remedy a disadvantage of the protein aggregate increase due to the mixing and addition of mannitol and arginine HCl and can improve thermodynamic / structural stability and the resulting stability during the long-term storage, and thus it is expected that the preparation can be advantageously used in the prevention, alleviation, and treatment of multiple sclerosis, cancer, autoimmune diseases, viral infectious diseases, HIV infectious diseases, hepatitis C, rheumatoid arthritis, and the like.

The invention discloses essence with a long-lasting moisturizing effect and a preparation method thereof. The essence is prepared from the following raw material components in percentage by mass: 5 to15 percent of long-lasting moisturizing complexing agent, 80 to 90 percent of solvent, 0.1 to 1 percent of thickener, 0.1 to 1 percent of pH conditioning agent, 0.5 to 1 percent of skin conditioner,0.2 to 1 percent of preservative and 0.05 to 0.5 percent of aromatic. The long-lasting moisturizing complexing agent is prepared from 10 to 25 percent of honey extract, 20 to 40 percent of rock mapleextract, 15 to 30 percent of saccharomycete / rice fermentation product filtrate, 0.5 to 5 percent of arginine HCl, 0.5 to 5 percent of lysine HCl, 0.5 to 5 percent of ornithine HCl, 0.5 to 5 percent ofceramide 3, 0.5 to 5 percent of ceramide 6II, 0.5 to 5 percent of ceramide 1, 10 to 20 percent of sodium lauroyl lactylate, 0.5 to 5 percent of phytosphingosine and 0.5 to 5 percent of cholesterol. The long-lasting moisturizing essence has a moisturizing effect lasting for 4 to 8 hours through optimization of the compounding and adding proportion of the long-lasting moisturizing complexing agent.

The invention relaets to a compound amino acid freeze-dried powder injection, which comprises L-arginine hydrochloride, L-histidine hydrochloride, L-leucine, L-isoleucine, L-lysine hydrochloride, L-phenylalanine, L-threonine, L-valine, L-methionine, L-tryptophan, glycine, L-alanine, L-proline, L-tyrosine, L-serine, L-cysteine hydrochloride, L- aspartic acid, L-glutamic acid and sodium bisulphate. Its preparing process is also disclosed in the invention.